智飞生物
(300122)
| 流通市值：281.16亿 | | | 总市值：475.89亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,069,009,417.19 | 2,700,466,763.66 | 3,263,949,292.31 | 5,586,109,730.2 |
| 应收票据及应收账款 | 14,645,413,281.08 | 16,272,763,249.18 | 21,391,675,746.63 | 25,471,988,622.99 |
| 应收账款 | 14,645,413,281.08 | 16,272,763,249.18 | 21,391,675,746.63 | 25,471,988,622.99 |
| 预付款项 | 40,406,471.57 | 45,612,057.91 | 59,640,771.04 | 55,738,490.03 |
| 其他应收款合计 | 9,326,586.33 | 10,952,388.39 | 10,300,183.84 | 8,016,555.54 |
| 存货 | 21,905,281,179.72 | 22,218,088,029.07 | 20,692,520,989.75 | 15,653,351,532.38 |
| 其他流动资产 | 5,927,560.01 | 8,106,399.42 | 2,973,707.68 | 16.8 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 39,675,364,495.9 | 41,292,988,542.93 | 45,458,060,346.55 | 46,812,204,603.24 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 291,000,000 | 295,000,000 | 295,000,000 | 295,000,000 |
| 投资性房地产 | 361,835 | 176,638.52 | 198,972.23 | 221,305.94 |
| 固定资产 | 4,431,003,448.31 | 4,337,774,955.95 | 3,621,578,779.29 | 3,701,659,404 |
| 在建工程 | 853,311,001.42 | 1,006,182,134.18 | 1,531,016,046.65 | 1,370,397,956.54 |
| 使用权资产 | 23,902,831.04 | 26,925,597.4 | 30,326,015.33 | 33,503,938.87 |
| 无形资产 | 563,712,830.38 | 300,263,604.23 | 300,647,626.01 | 304,929,457.75 |
| 开发支出 | 1,254,685,404.35 | 1,419,295,740.96 | 1,200,224,519.38 | 1,113,317,941.37 |
| 商誉 | 19,279,096.95 | 19,279,096.95 | 19,279,096.95 | 19,279,096.95 |
| 长期待摊费用 | 92,509,128.2 | 95,195,307.75 | 85,783,111.73 | 86,940,135.57 |
| 递延所得税资产 | 956,487,466.21 | 928,497,256.49 | 812,879,146.91 | 754,599,800.11 |
| 其他非流动资产 | 178,702,305.69 | 188,034,960.04 | 354,580,927.42 | 353,073,304.83 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 8,664,955,347.55 | 8,616,625,292.47 | 8,251,514,241.9 | 8,032,922,341.93 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 48,340,319,843.45 | 49,909,613,835.4 | 53,709,574,588.45 | 54,845,126,945.17 |
| 流动负债: | | | | |
| 短期借款 | 14,666,465,750.25 | 11,901,908,557.91 | 8,649,020,971.55 | 3,442,090,361.14 |
| 衍生金融负债 | 1,928,650.82 | - | - | - |
| 应付票据及应付账款 | 1,950,022,939.26 | 5,419,560,049.74 | 12,160,670,010.97 | 16,337,998,358.52 |
| 应付账款 | 1,950,022,939.26 | 5,419,560,049.74 | 12,160,670,010.97 | 16,337,998,358.52 |
| 预收款项 | 3,434,374.74 | 23,891,533.35 | 23,617,012.78 | 28,829,864 |
| 合同负债 | 11,629,221.91 | 11,869,634.92 | 10,075,699.57 | 5,567,854.59 |
| 应付职工薪酬 | 25,466,419.04 | 223,361,054.13 | 55,094,650.61 | 50,930,586.61 |
| 应交税费 | 183,436,791.64 | 394,462,353.73 | 307,522,291.03 | 497,101,620.56 |
| 其他应付款合计 | 272,983,659.8 | 372,431,976.47 | 364,917,238.26 | 2,228,747,342.84 |
| 应付股利 | - | - | - | 1,915,031,797.6 |
| 一年内到期的非流动负债 | 148,191,173.43 | 93,640,944.12 | 78,118,654.26 | 61,251,375.91 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 17,263,558,980.89 | 18,441,126,104.37 | 21,649,036,529.03 | 22,652,517,364.17 |
| 非流动负债: | | | | |
| 长期借款 | 279,440,292.91 | 347,588,788.71 | 334,507,804.14 | 379,080,866.29 |
| 租赁负债 | 16,706,979.02 | 15,447,210.27 | 18,953,997.75 | 19,078,272.31 |
| 递延收益 | 210,696,781.45 | 230,402,811.36 | 212,065,989.18 | 215,364,750.61 |
| 递延所得税负债 | 44,317,994.36 | 44,309,512.59 | 53,368,486.82 | 53,747,483.59 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 551,162,047.74 | 637,748,322.93 | 618,896,277.89 | 667,271,372.8 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 17,814,721,028.63 | 19,078,874,427.3 | 22,267,932,806.92 | 23,319,788,736.97 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,393,789,747 | 2,393,789,747 | 2,393,789,747 | 2,393,789,747 |
| 盈余公积 | 1,196,894,873.5 | 1,196,894,873.5 | 954,144,855.81 | 954,144,855.81 |
| 未分配利润 | 26,934,914,194.32 | 27,240,054,787.6 | 28,093,707,178.72 | 28,177,403,605.39 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 30,525,598,814.82 | 30,830,739,408.1 | 31,441,641,781.53 | 31,525,338,208.2 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 30,525,598,814.82 | 30,830,739,408.1 | 31,441,641,781.53 | 31,525,338,208.2 |
| 负债和股东权益合计 | 48,340,319,843.45 | 49,909,613,835.4 | 53,709,574,588.45 | 54,845,126,945.17 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-26 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |